ENTRY       D11366                      Drug
NAME        Dostarlimab (USAN);
            Dostarlimab-gxly;
            Jemperli (TN)
PRODUCT     JEMPERLI (GlaxoSmithKline LLC)
FORMULA     C6420H9832N1680O2014S44
EXACT_MASS  144094.6292
MOL_WEIGHT  144183.6677
SEQUENCE    (Heavy chain)
            EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYDMSWVRQA PGKGLEWVST ISGGGSYTYY
            QDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCASPY YAMDYWGQGT TVTVSSASTK
            GPSVFPLAPC SRSTSESTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
            LSSVVTVPSS SLGTKTYTCN VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP
            PKPKDTLMIS RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS
            VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS QEEMTKNQVS
            LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSRLTVDK SRWQEGNVFS
            CSVMHEALHN HYTQKSLSLS LGK
            (Light chain)
            DIQLTQSPSF LSAYVGDRVT ITCKASQDVG TAVAWYQQKP GKAPKLLIYW ASTLHTGVPS
            RFSGSGSGTE FTLTISSLQP EDFATYYCQH YSSYPWTFGQ GTKLEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H130-L214, H143-H199, H222-H'222, H225-H'225, H257-H317, H363-H421, H'22-H'96, H'130-L'214, H'143-H'199, H'257-H'317, H'363-H'421, L23-L88, L134-L194, L'23-L'88, L'194-L'134)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
REMARK      ATC code: L01FF07
            Product: D11366<US>
EFFICACY    Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody
  DISEASE   Endometrial cancer [DS:H00026]
  TYPE      Monoclonal antibody
TARGET      PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  PATHWAY   hsa04514(5133)  Cell adhesion molecules
            hsa04660(5133)  T cell receptor signaling pathway
            hsa05235(5133)  PD-L1 expression and PD-1 checkpoint pathway in cancer
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
                 L01FF07 Dostarlimab
                  D11366  Dostarlimab (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Dostarlimab
                D11366  Dostarlimab (USAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D11366  Dostarlimab
            Drug classes [BR:br08332]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D11366  Dostarlimab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                PDCD1 (PD1, CD279)
                 D11366  Dostarlimab (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11366
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11366
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11366
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D11366
DBLINKS     CAS: 2022215-59-2
            PubChem: 384585344
///
